Convalescent plasma therapy in patients with COVID-19.
COVID-19
Convalescent plasma
SARS-CoV-2
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
29
08
2020
revised:
01
09
2020
accepted:
06
09
2020
pubmed:
5
10
2020
medline:
30
3
2021
entrez:
4
10
2020
Statut:
ppublish
Résumé
Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19. The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively. Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (≤5 days, 6-10 days, 11-15 days) (p=0.001). CP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients.
Identifiants
pubmed: 33011076
pii: S1473-0502(20)30271-8
doi: 10.1016/j.transci.2020.102955
pmc: PMC7501849
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102955Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Curr Opin HIV AIDS. 2015 May;10(3):129-34
pubmed: 25760933
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Antimicrob Chemother. 2005 Nov;56(5):919-22
pubmed: 16183666
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Fa Yi Xue Za Zhi. 2020 Apr;36(2):157-163
pubmed: 32212512
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
J Clin Apher. 2020 Aug;35(4):367-373
pubmed: 32643200
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Clin Invest. 2020 Sep 1;130(9):4791-4797
pubmed: 32525844
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
J Med Virol. 2021 Feb;93(2):1099-1104
pubmed: 32776581
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347